• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jeffrey A. Engelman, M.D. Ph.D.

Assistant Professor, Department of Medicine, Harvard Medical School

Assistant Physician, Medical Oncology, Massachusetts General Hospital

Contact Info

Jeffrey Engelman
Massachusetts General Hospital
CNY 149, 13th Street
Charlestown, MA, 02129
Mailstop: Rm 7408
Phone: 617-724-7298
Fax: 617-724-9648
jengelman@partners.org

Assistant

Dana Engelman
Administrative Assistant
Medicine
Harvard Medical School
CNY 149, 13th Street
Charlestown, MA, 02129
Phone: 617-216-7657
Fax: 617-724-9648
dengelman1@partners.org

DF/HCC Program Affiliation

Cancer Cell Biology
Lung Cancer, Co-Leader

DF/HCC Associations

Member, Center Scientific Council
MGH, Lung, Clinical Trial Chairs

Research Abstract

Not Available.

Publications

  • Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK.Effective use of PI
    19029981
  • Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA.Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.J Clin Invest 2008 Jul;118(7):260
    18568074
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.MET Amplification Leads to Gefitinib Resistance in Lu
    17463250
  • Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA.Allelic dilution obscures detection of a biologically significant resistance mutatio
    16906227
  • Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Proc Natl Acad Sci U S A 2005 Mar 8;102(
    15731348